Predictors of Poor Prognosis in HFpEF

Clinical, Hemodynamic and Neurohumoral Predictors of Poor Prognosis in Heart Failure With Preserved Ejection Fraction

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06844032

Enrollment

500

Registered

2025-02-25

Start date

2022-01-31

Completion date

2026-12-31

Last updated

2026-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HFpEF

Keywords

HFpEF, HF, diastolic dysfunction, left ventricle (LV) filling pressures, left ventricular hypertrophy, cardiac reserves, myocardial fibrosis

Brief summary

Patients with HFpEF who have undergone meticulous clinical and instrumental evaluation (including diastolic exercise testing) between 2013 and 2020, will be followed up for at least 3 years.

Detailed description

Heart failure with preserved ejection fraction (HFpEF) is a serious condition with an unfavorable prognosis. The investigators aimed to evaluate in patients with HFpEF: * the prognostic significance of standard resting hemodynamic parameters compared to key cardiac reserves; * the prognostic significance of clinical parameters (sex, age, NYHA class, extra-cardiac diseases, therapy); * the prognostic significance of biological markers of hemodynamic stress and biomarkers of inflammation and fibrosis; * to identify independent predictors of adverse prognosis of HFpEF.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

40 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Signed and data informed consent; 2. New York Heart Association (NYHA) class II-III heart failure; 3. Left ventricular ejection fraction \> 50%; 4. Elevated LV filling pressures assessed by echocardiography at rest or at peak exercise.

Exclusion criteria

1. Evidence of myocardial ischemia during stress echocardiography; 2. Significant lesions of the main coronary arteries; 3. Genetic forms of HFpEF (HCM, amyloidosis, Fabry disease, glycogen storage diseases etc.); 4. Peripartum cardiomyopathy, chemotherapy-induced cardiomyopathy, viral myocarditis, isolated right-sided HF without left-sided structural disease, constrictive pericarditis, significant pericardial effusion; 5. Significant lung disease (severe lung disease requiring home oxygen or chronic oral steroid therapy); 6. Primary pulmonary artery hypertension; 7. Significant left-sided structural valve disease; 8. Anemia (Hb \< 100 g/L); 9. Impaired renal function, defined as estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m2 (CKD-EPI); 10. Non-cardiac conditions that complicate/exclude participation in the study; 11. Exacerbation of heart failure less than 3 months prior to study entry.

Design outcomes

Primary

Measure	Time frame
Hospitalization for exacerbation of HF	From enrollment to August 2026
All-cause mortality	From enrollment to August 2026

Countries

Russia

Contacts

CONTACTArtem G Ovchinnikov, MD, PhD, DSc

artcardio@mail.ru+74954146612

Outcome results